Michael Cap

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 269 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

Design and Synthesis of <i>N</i>-[(4-Methoxyphenoxy)carbonyl]-<i>N</i>-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

Pratik Devasthale, Sean Chen, Yoon Jeon et al. · Journal of Medicinal Chemistry · 2004 · 108 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Relation of Vascular Oxidative Stress, α-Tocopherol, and Hypercholesterolemia to Early Atherosclerosis in Hamsters

Rex A. Parker, Talal Sabrah, Michael Cap et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1995 · 105 citations · Full text

Life Sciences, Biochemistry, Nutritional Sciences +17

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11